TIAA CREF Investment Management LLC decreased its stake in CryoLife, Inc. (NYSE:CRY) by 17.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 95,834 shares of the medical equipment provider’s stock after selling 20,060 shares during the period. TIAA CREF Investment Management LLC’s holdings in CryoLife were worth $1,596,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Teachers Advisors LLC raised its stake in shares of CryoLife by 2.6% in the first quarter. Teachers Advisors LLC now owns 53,065 shares of the medical equipment provider’s stock valued at $884,000 after buying an additional 1,345 shares during the last quarter. Dialectic Capital Management LP bought a new stake in shares of CryoLife during the first quarter valued at about $2,238,000. Principal Financial Group Inc. raised its stake in shares of CryoLife by 3.9% in the first quarter. Principal Financial Group Inc. now owns 213,720 shares of the medical equipment provider’s stock valued at $3,558,000 after buying an additional 8,026 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its stake in shares of CryoLife by 3.2% in the first quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 190 shares during the last quarter. Finally, Arizona State Retirement System raised its stake in shares of CryoLife by 1.4% in the first quarter. Arizona State Retirement System now owns 14,054 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 200 shares during the last quarter. Institutional investors own 68.13% of the company’s stock.

CryoLife, Inc. (CRY) traded up 1.09% on Friday, reaching $18.55. 15,820 shares of the company were exchanged. The firm has a market capitalization of $620.42 million, a P/E ratio of 56.21 and a beta of 0.97. The firm has a 50-day moving average of $19.33 and a 200 day moving average of $17.96. CryoLife, Inc. has a 12-month low of $14.03 and a 12-month high of $20.30.

CryoLife (NYSE:CRY) last announced its earnings results on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.02. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business had revenue of $47.80 million during the quarter, compared to analysts’ expectations of $47.02 million. During the same period in the prior year, the company earned $0.13 earnings per share. The firm’s revenue was up 1.5% on a year-over-year basis. On average, equities analysts predict that CryoLife, Inc. will post $0.43 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/11/cryolife-inc-nysecry-shares-sold-by-tiaa-cref-investment-management-llc.html.

Several brokerages have recently issued reports on CRY. Zacks Investment Research lowered shares of CryoLife from a “buy” rating to a “sell” rating in a research note on Wednesday, August 2nd. BidaskClub lowered shares of CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Northland Securities reiterated a “buy” rating and issued a $23.50 price objective on shares of CryoLife in a research note on Friday, April 28th. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $22.00.

In other CryoLife news, VP Amy Horton sold 9,577 shares of the company’s stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total transaction of $191,540.00. Following the completion of the sale, the vice president now directly owns 112,282 shares of the company’s stock, valued at $2,245,640. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 6.00% of the stock is currently owned by corporate insiders.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife, Inc. (NYSE:CRY).

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.